Effective antibody removal using PE, DFPP and IA has led to increased access to live donor organs through ABOi RT for patients with chronic kidney disease. However, there have been no head-to-head comparator studies between these modalities, and the choice of technique is usually influenced by cost and institutional preference. We describe the clinical course of a child undergoing ABOi RT, in whom IA without preconditioning with rituximab did not achieve a satisfactory reduction in the antibody titers, who went on to have a successful living donor RT following rituximab and DFPP.
Keywords: ABOi kidney transplant; double filtration plasmapheresis; immunoadsorption; rituximab.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.